News

Neumentum snags $6 mln Series A

Palo Alto, California-based Neumentum, a developer of non-opioid pain products, has raised $6 million in Series A funding. The backers were not named. Brookline Capital Markets was the placement agent.

AmorChem closes second early-stage biotech fund at $44.2 mln

AmorChem Group has launched AmorChem II Fund LP, a seed-stage biotechnology investor, at an initial capitalization of $44.2 million. The fund secured commitments from the Québec government, Fonds de solidarité FTQ, U.S. pharmaceutical giant Merck and other limited partners. AmorChem, which now manages $86 million, invests in promising life sciences projects originating from Québec universities and research centres that can be built into startups able to attract investors and pharmaceutical partners. The Montréal investor is led by General Partners Elizabeth Douville and Inès Holzbaur. A new general partner, Maxime Ranger, joined with Fund II's launch.

Viola amasses $100 mln for fintech fund

Israel-based tech investor Viola has raised $100 million for its new global fintech fund. The target is $120 million to $150 million. The fund's backers include Scotiabank, The Travelers Companies Inc and Bank Hapoalim.

Anzu Partners raises $128.4 mln for maiden fund

Anzu Partners has closed its inaugural fund at $128.4 million. Anzu Industrial Capital Partners LP will invest in American and Canadian private industrial technology companies. The fund's limited partners include institutions, family offices and individuals in the U.S. and overseas.

AmorChem collects $44.2 mln for second fund

Montreal-based AmorChem, a life sciences venture firm, has raised $44.2 million for its second fund. AmorChem II will focus on backing "promising" life science projects originating from Québec-based universities and research centers. The fund's limited partners include the Québec government, Fonds de solidarité FTQ and Merck.

Obsidian Therapeutics scores $49.5 mln Series A

Cambridge, Massachusetts-based Obsidian Therapeutics Inc, a biotechnology company, has closed $49.5 million in Series A financing. GV led the round with participation from Atlas Venture, Takeda Ventures Inc, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments and ShangPharma Investment Group. In addition to the funding, Obsidian has named Dr. Michael Gilman as CEO.

HealthiPass gathers $7.2 mln Series A

HealthiPass, a patient-centric digital payments platform, has raised $7.2 million in Series A funding. FCA Venture Partners led the round with participation from other investors that included OCA Ventures, Healthy Ventures, HealthX Ventures and Waterline Ventures.

LA seed firm CrossCut wraps up fourth fund with $125 mln

Jump Capital raises $100 mln venture fund

Jump Capital has raised a $100 million venture fund, according to a filing with the SEC.

Initial Coin Offering Group raising indefinite fund